Cidara Therapeutics to Host Investor Day on April 6, 2017
Interested parties may access a live audio webcast and slides of the presentations on the investor section of Cidara’s website at www.cidara.com beginning at
About
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through a Phase 2 study and developing CD201, its bispecific antimicrobial immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has enhanced potency and is the only once-weekly therapy intended for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in
INVESTOR CONTACT:Robert H. Uhl Westwicke Partners, LLC Managing Director (858) 356-5932 robert.uhl@westwicke.com MEDIA CONTACT:Christy Curran Sam Brown Inc. (615) 414-8668 ChristyCurran@sambrown.com